Abstract: Disclosed in the present invention are a crystal form and salt form of a TGF-?R1 inhibitor and a preparation method therefor, and further disclosed is an application of the crystal form and the salt form in preparation of medicines for treating cancers.

Abstract: Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor.

Abstract: The present disclosure discloses a faucet device with a self-cleaning function, comprising: a faucet mechanism, a control mechanism, a self-cleaning mechanism, and a beverage inlet passage. The beverage inlet passage is configured to be in communication with a beverage source, the faucet mechanism comprises a first passage configured to be in communication with a water source and a second passage configured to be in communication with a beverage source, and the control mechanism is connected to an inlet of the second passage, the beverage inlet passage, and the self-cleaning mechanism to control the beverage inlet passage to supply a beverage supplied by the beverage source to the second passage or to enable the second passage to be cleaned by the self-cleaning mechanism.

Abstract: Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Specifically, disclosed are a compound represented by formula (I) and a pharmacologically acceptable salt thereof.

Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer.

Abstract: Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor.

Abstract: Disclosed are a crystal form of a c-MET inhibitor and a salt form thereof and a preparation method therefor. Specifically involved are the compound as shown in formula (I), and a salt form and a crystal form thereof, and also included is the use of the crystal form and the salt form in the preparation of medicines for treating cancers.

Abstract: The present disclosure a waterway switching valve. A valve body comprises a water inlet, a first water outlet, and a second water outlet. The switching operating member is operatively connected to the switching member. The switching member is sequentially disposed with a first sealing member, a first pressure relief member, a second pressure relief member, and a second sealing member along a moving direction of the switching member. A first pressure generating cavity and a second pressure generating cavity are disposed in the valve body, and a blocking member is disposed in the valve body between the first pressure generating cavity and the second pressure generating cavity. The blocking member comprises a first flow passage and a second flow passage isolated from the first flow passage, and the first flow passage and the second flow passage are respectively in communication with the first water outlet and the second water outlet.

Abstract: Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.

Abstract: Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer.

Abstract: An automatically resettable press-type switching valve includes a valve housing, an operating portion, a driven rod, a water blocking member, and a resetting member. The valve housing is formed therein with an inlet and outlet passages. A water blocking seat is provided between the inlet and outlet passages. The operating portion drives the driven rod to move axially so as to form a forward pressure difference or reverse pressure difference between two opposing sides of the water blocking member, by which the water blocking member is pushed to move axially with the driven rod. The resetting member is drivingly connected with the water blocking member, when there is no water pressure at a side of the inlet passage, the resetting member drives the water blocking member to separate from the water blocking seat, and the inlet passage is communicated with the outlet passage.

Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a waterway switch switching valve, which comprises: valve body, main control valve core and waterway control valve core; the valve body comprises a water inlet channel, a first water outlet and a second water outlet, the number of waterway control valve core corresponds to the number of water outlets one by one, and is divided into the first and second waterway control valve core; the first waterway control valve core and the second waterway control valve core are respectively installed in the valve body; The valve body also comprises a first waterway arranged between the water inlet channel and the first waterway control valve core; and a second waterway between the first waterway control valve core and the second waterway control valve core; when the first waterway control valve core is opened, the first waterway control valve core connects the first waterway with the first water outlet; when the first waterway control valve core is closed, the first waterway control valve core connec

Abstract: A water outlet device with water stop and flow rate control comprises a body, a water stop assembly, and a flow rate control assembly. The body comprises a water outflow passage. The flow rate control assembly and the water stop assembly are disposed on the body, first ends of the water stop assembly and the flow rate control assembly are respectively disposed in the water outflow passage, and second ends of the water stop assembly and the flow rate control assembly are exposed out of the body to respectively define a water stop operation end and a flow rate control end. The water stop assembly comprises a first shaft that is operatively connected to the water stop operation end. The flow rate control assembly comprises a second shaft that is operatively connected to the flow rate control end.

Abstract: A salt serving as an Akt inhibitor and a crystal thereof, specifically related to a salt of the compound of formula (I) and a crystal thereof.

Abstract: The present disclosure discloses a fixing device and a faucet installation device. The fixing device comprises a base and a pressing block mechanism. The pressing block mechanism comprises two pressing plates. The two pressing plates are respectively connected to a locking rod, and an inner side wall of the base protrudes to define two connecting bases. At least one of the locking rods is configured to move relative to the base between a working state and a movable state. Movement of the at least one of the locking rods between the working state and the movable state cooperates with the change of the pressing block mechanism between the unfolded state and the folded state.

Abstract: Disclosed in the present invention are a crystal form and salt form of a TGF-?R1 inhibitor and a preparation method therefor, and further disclosed is an application of the crystal form and the salt form in preparation of medicines for treating cancers.

Abstract: Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor down-regulator. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor down-regulator in the treatment of estrogen receptor positive breast cancers.

Abstract: An outlet device includes an electronic outlet mode and a mechanical outlet mode. The outlet device has a mechanical outlet control device, an electronic outlet control device and a central control module. The central control module comprises a first outlet passage controlled by the mechanical outlet control device, a second outlet passage controlled by the electronic outlet control device, and a central controller. The first outlet passage includes a sensor and the second outlet passage includes an electromagnetic valve. When the mechanical outlet control device controls the first outlet passage to open, the sensor detects water flowing in the first outlet passage, whether the electromagnetic valve opens or not, the central controller switches the electromagnetic value to a normal closed state.